Dr Stephen Scott MacKinnon PhD

Cyclica is a Toronto-based, globally recognized biotechnology company developing predictive technologies to reshape the drug discovery process. Stephen designed and led the development of Cyclica's first market technology, LigandExpress, which provides a panoramic prediction of a drug's unintended effects on biological systems at the molecular level. He now oversees the research and development at Cyclica for new computational technologies, from ideation to market. He completed a B.Sc. in Computational Sciences at the University of Waterloo and PhD studying Computational Biochemistry at the University of Toronto.